Literature DB >> 12023400

Functional heterogeneity of vaccine-induced CD8(+) T cells.

Vladia Monsurrò1, Dirk Nagorsen, Ena Wang, Maurizio Provenzano, Mark E Dudley, Steven A Rosenberg, Francesco M Marincola.   

Abstract

The functional status of circulating vaccine-induced, tumor-specific T cells has been questioned to explain their paradoxical inability to inhibit tumor growth. We enumerated with HLA-A*0201/peptide tetramers (tHLA) vaccine-elicited CD8(+) T cell precursor frequency among PBMC in 13 patients with melanoma undergoing vaccination with the HLA-A*0201-associated gp100:209-217(210 M) epitope. T cell precursor frequency increased from undetectable to 12,400 +/- 3,600 x 10(6) CD8(+) T cells after vaccination and appeared heterogeneous according to previously described functional subtypes: CD45RA(+)CD27(+) (14 +/- 2.6% of tHLA-staining T cells), naive; CD45RA(-)CD27(+) (14 +/- 3.2%), memory; CD45RA(+)CD27(-) (43 +/- 6%), effector; and CD45RA(-)CD27(-) (30 +/- 4.1%), memory/effector. The majority of tHLA(+)CD8(+) T cells displayed an effector, CD27(-) phenotype (73%). However, few expressed perforin (17%). Epitope-specific in vitro stimulation (IVS) followed by 10-day expansion in IL-2 reversed this phenotype by increasing the number of perforin(+) (84 +/- 3.6%; by paired t test, p < 0.001) and CD27(+) (from 28 to 67%; by paired t test, p = 0.01) tHLA(+) T cells. This conversion probably represented a change in the functional status of tHLA(+) T cells rather than a preferential expansion of a CD27(+) (naive and/or memory) PBMC, because it was reproduced after IVS of a T cell clone bearing a classic effector phenotype (CD45RA(+)CD27(-)). These findings suggest that circulating vaccine-elicited T cells are not as functionally active as inferred by characterization of IVS-induced CTL. In addition, CD45RA/CD27 expression may be more informative about the status of activation of circulating T cells than their status of differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023400      PMCID: PMC2553240          DOI: 10.4049/jimmunol.168.11.5933

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP).

Authors:  M Bunce; C M O'Neill; M C Barnardo; P Krausa; M J Browning; P J Morris; K I Welsh
Journal:  Tissue Antigens       Date:  1995-11

2.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.

Authors:  M Marchand; P Weynants; E Rankin; F Arienti; F Belli; G Parmiani; N Cascinelli; A Bourlond; R Vanwijck; Y Humblet
Journal:  Int J Cancer       Date:  1995-12-11       Impact factor: 7.396

3.  Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

Authors:  F M Marincola; L Rivoltini; M L Salgaller; M Player; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-07

Review 4.  Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones.

Authors:  S R Riddell; P D Greenberg
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

5.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Authors:  M R Parkhurst; M L Salgaller; S Southwood; P F Robbins; A Sette; S A Rosenberg; Y Kawakami
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

Review 6.  Is cancer dangerous to the immune system?

Authors:  E J Fuchs; P Matzinger
Journal:  Semin Immunol       Date:  1996-10       Impact factor: 11.130

7.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

8.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

Authors:  M L Salgaller; F M Marincola; J N Cormier; S A Rosenberg
Journal:  Cancer Res       Date:  1996-10-15       Impact factor: 12.701

10.  Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

Authors:  L Rivoltini; Y Kawakami; K Sakaguchi; S Southwood; A Sette; P F Robbins; F M Marincola; M L Salgaller; J R Yannelli; E Appella
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

View more
  20 in total

1.  Structural engineering of pMHC reagents for T cell vaccines and diagnostics.

Authors:  Vesselin Mitaksov; Steven M Truscott; Lonnie Lybarger; Janet M Connolly; Ted H Hansen; Daved H Fremont
Journal:  Chem Biol       Date:  2007-08

2.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

Review 3.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

4.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Authors:  Hideho Okada; Pawel Kalinski; Ryo Ueda; Aki Hoji; Gary Kohanbash; Teresa E Donegan; Arlan H Mintz; Johnathan A Engh; David L Bartlett; Charles K Brown; Herbert Zeh; Matthew P Holtzman; Todd A Reinhart; Theresa L Whiteside; Lisa H Butterfield; Ronald L Hamilton; Douglas M Potter; Ian F Pollack; Andres M Salazar; Frank S Lieberman
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

5.  Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition.

Authors:  Ching Y Voss; Sara Deola; Thomas A Fleisher; Francesco M Marincola
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

6.  Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.

Authors:  D Nagorsen; M Panelli; M E Dudley; S E Finkelstein; S A Rosenberg; F M Marincola
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

Review 7.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

8.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

9.  Cancer microenvironment and cancer vaccine.

Authors:  Zhen-Yu Ding; Xue-Lin Zou; Yu-Quan Wei
Journal:  Cancer Microenviron       Date:  2012-05-06

10.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.